Topic sponsors are not involved in the creation of editorial content. "With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL" was originally created and published by ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed CAR T cell therapy, Breyanzi, met its primary ...

accounting for up to 30% of cases Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel) has been recommended by the European Medicines Agency’s human medicines committee to treat follicular ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but ... the data would give BMS an opportunity to take Breyanzi into so-far uncharted ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but ... the data would give BMS an opportunity to take Breyanzi into so-far uncharted ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive ... Rosanna Ricafort, BMS’ head of hematology and cell therapy late development ...

Marginal zone lymphoma, a slow-growing NHL, accounts for 7% of cases and presents in extranodal, nodal, and splenic forms. Breyanzi demonstrated efficacy in a fifth cancer type, the most among ...

Drawing from their unique experiences, five insights are offered for managing the chimeric antigen receptor (CAR) T cell therapy journey as a caregiver. Breyanzi, a prescription medicine ...

Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. Breyanzi is made from a patient’s own T cells ...

PRINCETON, N.J., January 31, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...